Role of myeloid-derived suppressor cells in tumor immunotherapy

Immunotherapy

Volumn 4, Issue 1, 2012, Pages 43-57

  Martin, Franois ^a   Apetoh, Lionel ^a,b   Ghiringhelli, François ^a,b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b Department of Medical Oncology   (France)

Author keywords

ATRA; cancer; exosome; fluorouracil; gemcitabine; immunotherapy; myeloid derived suppressor cells; sildenafil; STAT3; sunitinib

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; BARDOXOLONE METHYL; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PACLITAXEL; RETINOIC ACID; SILDENAFIL; SUNITINIB; TADALAFIL; VARDENAFIL; ZOLEDRONIC ACID;

CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL HETEROGENEITY; ERECTILE DYSFUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TUMOR; TUMOR GROWTH;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; MYELOID CELLS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 83655196899     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.154     Document Type: Review

References (105)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
2. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer- what clinicians need to know. Nat. Rev. Clin. Oncol. 8, 577-585 (2011).
3. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy - revisited. Nat. Rev. Drug Discov. 10, 591-600 (2011).
4. 25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336-344 (2004). (Pubitemid 39255944)
5. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front. Biosci. 13, 453-461 (2008). (Pubitemid 351599757)
6. Manrique SZ, Correa MA, Hoelzinger DB et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J. Exp. Med. 208, 1485-1499 (2011).
7. Bronte V. Tolerogenic pDCs: Spotlight on Foxo3. J. Clin. Invest. 121, 1247-1250 (2011).
8. Watkins SK, Zhu Z, Riboldi E et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121, 1361-1372 (2011).
9. Munder M. Arginase: An emerging key player in the mammalian immune system. Br. J. Pharmacol. 158, 638-651 (2009).
10. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J. Immunol. 166(1), 678-689 (2001). (Pubitemid 32038493)
11. Bronte V, Apolloni E, Cabrelle A et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96, 3838-3846 (2000).
12. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166, 5398-5406 (2001). (Pubitemid 32374159)
13. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 70, 325-330 (2009).
14. Gabrilovich DI, Bronte V, Chen SH et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67, 425 (2007). (Pubitemid 46142802)
15. Bronte V. Myeloid-derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions. Eur. J. Immunol. 39, 2670-2672 (2009).
16. Sander LE, Sackett SD, Dierssen U et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 207, 1453-1464 (2010).
17. Nicholson LB, Raveney BJ, Munder M. Monocyte dependent regulation of autoimmune inflammation. Curr. Mol. Med. 9, 23-29 (2009).
18. Highfill SL, Rodriguez PC, Zhou Q et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116, 5738-5747 (2010).
19. Umemura N, Saio M, Suwa T et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol. 83, 1136-1144 (2008). (Pubitemid 351960345)
20. Lu T, Ramakrishnan R, Altiok S et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121, 4015-4029 (2011).
21. Peranzoni E, Zilio S, Marigo I et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238-244 (2010).
22. Ugel S, Delpozzo F, Desantis G et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr. Opin. Pharmacol. 9, 470-481 (2009).
23. Matzer SP, Rö del F, Strieter RM, Rö llinghoff M, Beuscher HU. Constitutive expression of CXCL2/MIP-2 is restricted to a Gr-1high, CD11b+, CD62Lhigh subset of bone marrow derived granulocytes. Int. Immunol. 16, 1675-1683 (2004). (Pubitemid 39480786)
24. Tomihara K, Guo M, Shin T et al. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J. Immunol. 184, 6151-6160 (2010).
25. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802 (2008).
26. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 11, 802-806 (2011).
27. Rodriguez PC, Ernstoff MS, Hernandez C et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69, 1553-1560 (2009).
28. Brandau S, Trellakis S, Bruderek K et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. Leukoc. Biol. 89, 311-317 (2011).
29. 8+T lymphocytes in patients with advanced-stage non-small-cell lung cancer. J. Cancer Res. Clin. Oncol. 136, 35-45 (2010).
30. Hoechst B, Ormandy LA, Ballmaier M et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135, 234-243 (2008). (Pubitemid 351899008)
31. Zhao F, Obermann S, von Wasielewski R et al. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 128, 141-149 (2009).
32. Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 69, 5514-5521 (2009).
33. Younos I, Donkor M, Hoke T et al. Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells. Int. Immunopharmacol. 11, 816-826 (2011).
34. Donkor MK, Lahue E, Hoke TA et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int. Immunopharmacol. 9, 937-948 (2009).
35. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59 (2009).
36. 14+HLA-DRlow/- monocytes in prostate cancer. Prostate 70, 443-455 (2010).
37. Zea AH, Rodriguez PC, Atkins MB et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res. 65, 3044-3048 (2005). (Pubitemid 40524582)
38. 14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-SIGN. Cancer Res. 70, 4335-4345 (2010).
39. 14+HLA-DR-/ low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand. J. Immunol. 72, 540-547 (2010).
40. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499-4506 (2009).
41. Ueha S, Shand FH, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int. Immunopharmacol. 11, 783-788 (2011).
42. Pan PY, Wang GX, Yin B et al. Reversion of immune tolerance in advanced malignancy: Modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111, 219-228 (2008).
43. Dolcetti L, Peranzoni E, Ugel S et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40, 22-35 (2010).
44. Saleem SJ, Conrad DH. Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSCs expansion. Int. Immunopharmacol. 11, 807-813 (2011).
45. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 185, 2273-2284 (2010).
46. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51 (2007). (Pubitemid 46020826)
47. Ko JS, Rayman P, Ireland J et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70, 3526-3536 (2010).
48. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
49. Corzo CA, Cotter MJ, Cheng P et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol.182, 5693-5701 (2009).
50. Thery C, Zitvogel L, Amigorena S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2, 569-579 (2002).
51. Xiang X, Poliakov A, Liu C et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621-2633 (2009).
52. Chalmin F, Ladoire S, Mignot G et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457-471 (2010).
53. Solito S, Bronte V, Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J. Leukoc. Biol. 90, 31-36 (2011).
54. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13, 5243-5248 (2007). (Pubitemid 47510346)
55. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59, 1593-1600 (2010).
56. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184, 3106-3116 (2010).
57. Mundy-Bosse BL, Lesinski GB, Jaime- Ramirez AC et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 71, 5101-5110 (2011).
58. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180-191 (2008). (Pubitemid 351430370)
59. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70, 68-77 (2010).
60. Huang B, Pan PY, Li Q et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131 (2006). (Pubitemid 43165981)
61. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68, 5439-5449 (2008).
62. Movahedi K, Guilliams M, Van den Bossche J et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233-4244 (2008).
63. Cheng P, Corzo CA, Luetteke N et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
64. Hoechst B, Voigtlaender T, Ormandy L et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50, 799-807 (2009).
65. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-b 1. J. Immunol. 182, 240-249 (2009).
66. Elkabets M, Ribeiro VS, Dinarello CA et al. IL-1b regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40, 3347-3357 (2010).
67. Greifenberg V, Ribechini E, Rö ssner S, Lutz MB. Myeloid-derived suppressor cell activation by combined LPS and IFN-g treatment impairs DC development. Eur. J. Immunol. 39, 2865-2876 (2009).
68. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179, 977-983 (2007).
69. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit. Rev. Oncol. Hematol. 77, 12-19 (2011).
70. Brusa D, Carletto S, Cucchiarale G et al. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes. Prostate 71, 344-352 (2011).
71. Wicherek L, Jozwicki W, Windorbska W et al. Analysis of Treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer - a preliminary report. Am. J. Reprod. Immunol. 66(5), 444-450 (2011).
72. Tokuno K, Hazama S, Yoshino S, Yoshida S, Oka M. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res. 29, 1527-1532 (2009).
73. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766 (2000). (Pubitemid 30305068)
74. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65, 11743-11751 (2005). (Pubitemid 41821736)
75. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123, 39-49 (2010).
76. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103 (1996). (Pubitemid 26338628)
77. Fricke I, Mirza N, Dupont J et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13, 4840-4848 (2007). (Pubitemid 47298146)
78. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inucing myeloid-derived suppressor cells. Cancer Res. 67, 4507-4513 (2007). (Pubitemid 46815102)
79. Veltman JD, Lambers ME, van Nimwegen M et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSCs function. BMC Cancer 10, 464 (2010).
80. Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109, 625-637 (2002). (Pubitemid 34628725)
81. Yang L, DeBusk LM, Fukuda K et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004). (Pubitemid 39361441)
82. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67, 11438-11446 (2007). (Pubitemid 350248572)
83. Suzuki E, Kapoor V, Jassar AS, Kaiser L, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721 (2005). (Pubitemid 41339014)
84. Ko HJ, Kim YJ, Kim YS et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67, 7477-7486 (2007).
85. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 9, 900-909 (2009).
86. Vincent J, Mignot G, Chalmin F et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061 (2010).
87. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16, 4583-4594 (2010).
88. Mirza N, Fishman M, Fricke I et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299-9307 (2006). (Pubitemid 44521152)
89. Kusmartsev S, Su Z, Heiser A et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14, 8270-8278 (2008).
90. De Santo C, Serafini P, Marigo I et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl Acad. Sci. USA 102, 4185-4190 (2005). (Pubitemid 40388577)
91. Serafini P, Meckel K, Kelso M et al. Phosphodiesterase-5 inhibition. augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203, 2691-2702 (2006). (Pubitemid 44833345)
92. 8+T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989-999 (2004). (Pubitemid 38113758)
93. Nagaraj S, Youn JI, Weber H et al. Antiinflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. 16, 1812-1823 (2010).
94. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69, 2506-2513 (2009).
95. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148-2157 (2009).
96. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSCs as a mechanism of tumor escape from sunitinib mediated antiangiogenic therapy. Int. Immunopharmacol. 11, 856-861 (2011).
97. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59-73 (2008).
98. Kusmartsev S, Cheng F, Yu B et al. All-trans-retinoic acid eliminates immature myeloid cells from tumorbearing mice and improves the effect of vaccination. Cancer Res. 63, 4441-4449 (2003). (Pubitemid 36951016)
99. Bose A, Taylor JL, Alber S et al. Sunitinib facilitates the activation and recruitment of therapeutic antitumor immunity in concert with specific vaccination. Int. J. Cancer 129, 2158-2170 (2011).
100. Finkelstein SE, Carey T, Fricke I et al. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J. Immunother. 33, 817-827 (2010).
101. Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691-1701 (2005). (Pubitemid 41815875)
102. Tesniere A, Schlemmer F, Boige V et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482-491 (2010).
103. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007). (Pubitemid 46067386)
104. 25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J. Clin. Invest. 118, 3751-3761 (2008).
105. Corzo CA, Condamine T, Lu L et al. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207, 2439-2453 (2010).